SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-21-001407
Filing Date
2021-02-23
Accepted
2021-02-23 07:01:35
Documents
15
Period of Report
2021-02-23
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20210223x8k.htm   iXBRL 8-K 35265
2 EX-99.1 plx-20210223xex99d1.htm EX-99.1 26051
3 GRAPHIC plx-20210223xex99d1002.jpg GRAPHIC 6293
4 GRAPHIC plx-20210223xex99d1001.jpg GRAPHIC 5207
  Complete submission text file 0001558370-21-001407.txt   208798

Data Files

Seq Description Document Type Size
5 EX-101.SCH plx-20210223.xsd EX-101.SCH 3248
6 EX-101.LAB plx-20210223_lab.xml EX-101.LAB 16112
7 EX-101.PRE plx-20210223_pre.xml EX-101.PRE 10896
8 EXTRACTED XBRL INSTANCE DOCUMENT plx-20210223x8k_htm.xml XML 4864
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401 972-4-988-9488
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 21663022
SIC: 2836 Biological Products, (No Diagnostic Substances)